← Leaderboards
Rebecca Eh Whiting
University Of Missouri-Columbia
$2,365,077
Attributed
$2,365,077
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $536K · FY2019–23$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,365,077 · 1
By mechanism
R01$2,365,077 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Missouri-Columbia
Same institution · by research overlap
- Martin L Katz$6,047,835
- Joe N Kornegay$9,157,041
- Martin K. Childers$7,329,077
- Raghuraman Kannan$5,372,272
- Joan Ripley Coates$645,522
Research focus
Tripeptidyl AminopeptidaseBlindnessNerve DegenerationSeizuresVisualChildhoodImplantationMutationRetinaSafetyVisual ImpairmentVisual ProcessingBrainCognitiveAutologousEnzymesMesenchymal Stem CellsMotorNeuronal Ceroid-LipofuscinosisPathologyBiochemicalAftercareClinical TrialsBehavior
Grant awards (8)
Sustained delivery of therapeutics to the visual system using genetically modified autologous mesenchymal stem cells to treat blinding diseases$378,466
R01 · FY2023 · EY · contact PI
Sustained delivery of therapeutics to the visual system using genetically modified autologous mesenchymal stem cells to treat blinding diseases$155,370
R01 · FY2023 · EY · contact PI
Sustained delivery of therapeutics to the visual system using genetically modified autologous mesenchymal stem cells to treat blinding diseases$365,652
R01 · FY2022 · EY · contact PI
Sustained delivery of therapeutics to the visual system using genetically modified autologous mesenchymal stem cells to treat blinding diseases$155,370
R01 · FY2022 · EY · contact PI
Sustained delivery of therapeutics to the visual system using genetically modified autologous mesenchymal stem cells to treat blinding diseases$464,195
R01 · FY2021 · EY · contact PI
Sustained delivery of therapeutics to the visual system using genetically modified autologous mesenchymal stem cells to treat blinding diseases$477,524
R01 · FY2020 · EY · contact PI
Sustained delivery of therapeutics to the visual system using genetically modified autologous mesenchymal stem cells to treat blinding diseases$58,500
R01 · FY2020 · EY · contact PI
Sustained delivery of therapeutics to the visual system using genetically modified autologous mesenchymal stem cells to treat blinding diseases$310,000
R01 · FY2019 · EY · contact PI